{"version":"1.0","width":"100%","image_url":null,"provider_name":"Hatena Blog","url":"https://ryamada22.hatenablog.jp/entry/20090328/1238278289","blog_title":"ryamada\u306e\u907a\u4f1d\u5b66\u30fb\u907a\u4f1d\u7d71\u8a08\u5b66\u30e1\u30e2","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fryamada22.hatenablog.jp%2Fentry%2F20090328%2F1238278289\" title=\"\u75be\u60a3\u95a2\u9023\u907a\u4f1d\u5b50\u89e3\u6790\u30c7\u30fc\u30bf\u306e\u89e3\u91c8\u3068\u81e8\u5e8a\u5fdc\u7528 - ryamada\u306e\u907a\u4f1d\u5b66\u30fb\u907a\u4f1d\u7d71\u8a08\u5b66\u30e1\u30e2\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","published":"2009-03-28 07:11:29","author_name":"ryamada22","description":"Beyond odds ratios --- communicating disease risk based on genetic profiles. P Kraft et al. nat reviews genet 10:264-268 2009 p,odds ratio, population attributable risk(PAR), sensitivity, specificity, PPV, NPV Clinical validity ACCE (Analytic validity, Clinical validity, Clinical utility and associa\u2026","author_url":"https://blog.hatena.ne.jp/ryamada22/","blog_url":"https://ryamada22.hatenablog.jp/","type":"rich","title":"\u75be\u60a3\u95a2\u9023\u907a\u4f1d\u5b50\u89e3\u6790\u30c7\u30fc\u30bf\u306e\u89e3\u91c8\u3068\u81e8\u5e8a\u5fdc\u7528","height":"190","categories":["\u8ad6\u6587","\u75be\u60a3\u95a2\u9023\u907a\u4f1d\u5b50\u89e3\u6790","\u95a2\u9023\u89e3\u6790","\u6587\u732e","\u3071\u3089\u3071\u3089\u3081\u304f\u308b\u30b7\u30ea\u30fc\u30ba"],"provider_url":"https://hatena.blog"}